Fluid Biomed has closed an oversubscribed $27M USD Series A round, co-led by Amplitude Ventures and an undisclosed partner. Investors include IAG Capital, LifeArc Ventures, and others.
The funding will scale development and trials of the ReSolv™ stent, a bioabsorbable device for treating brain aneurysms, which impact 6.7M Americans annually. Unlike metallic stents, ReSolv™ reduces long-term risks by absorbing into the body. Co-founders Dr. John Wong and Dr. Alim Mitha, neurosurgeons at the University of Calgary, aim to improve global patient outcomes with this breakthrough technology. Clinical trials and pipeline expansion are next.
Want to know more? Check out the source code on Calgary.tech.